« Return to News | Awards & Advancement

Recipharm appoints Lennernäs to operating board

Wednesday, February 6, 2013 12:38 PM

Recipharm, a contract development and manufacturing organization based in Sweden, has appointed Dr. Hans Lennernäs to the operating board of Recipharm Pharmaceutical Development.

Lennernäs is a professor of biopharmaceutics at Uppsala University. He currently manages an IMI project entitled OrBiTo, which aims to improve oral drug delivery; controlling a budget of 24.5 MEuro. His research responsibilities and remit are focused on membrane transport and metabolism of drugs/metabolites in the gastrointestinal tract, hepatobiliary system and cancer tissues.

Lennernäs has served as the Principal Investigator in an extensive collaboration with the FDA, University of Michigan and Medical Product Agency of Sweden over the course of several years in which he developed a new guideline for the biopharmaceutics classification system. He has established an extensive and widely used human permeability database.

In addition to his academic achievements, Lennernäs has built an entrepreneurial reputation  by co-founding  several companies including DuoCort Pharma and LIDDS, while investing in a number of patents.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.